Skip to main content

Table 2 Demographic and clinical characteristic of adult study participants

From: Age and fecal microbial strain-specific differences in patients with spondyloarthritis

Characteristic

SpA

Controls

n

11

10

Age (years), mean ± SD

52 ± 7.4

47 ± 8.1

BMI (kg/m2), mean ± SD

32 ± 7.8

28 ± 4.8

Disease duration (years), mean ± SD

11 ± 9.5

Not applicable

Male

4 (36%)

3 (30%)

Race

 Caucasian

9 (82%)

6 (60%)

 African-American

2 (18%)

4 (40%)

Diagnosis

 

Not applicable

 Undifferentiated SpA

1 (9.1%)

 Ankylosing spondylitis

6 (54%)

 IBD-associated arthritis

1 (9.1%)

 Psoriatic arthritis

2 (18%)

 Reactive arthritis

1 (9.1%)

Current medications

 None

2 (18%)

10 (100%)

 Traditional DMARDs alone

5 (45%)

 TNFi alone

3 (27%)

 DMARDs plus TNFi

1 (9.1%)

HLA-B27+

3/3 (100%)

Not measured

Sacroiliitis

8 (73%)

None

 Clinical

1 (12%)

 Imaging

7 (88%)

  1. Data presented as n (%) unless stated otherwise
  2. BMI body mass index, DMARD disease-modifying anti-rheumatic drug (leflunomide, n = 2; methotrexate, n = 2; sulfasalazine, n = 3), IBD inflammatory bowel disease, SpA spondyloarthritis, TNFi tumor necrosis factor inhibitor